MDXH Key Statistics, Chart & Performance
The current stock price of MDXH is 3.47 USD. In the past month the price decreased by -28.31%. In the past year, price increased by 72.64%.
MDXH Latest News, Press Relases and Analysis
MDXH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About MDXH
Company Profile
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege and currently employs 312 full-time employees. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Company Info
MDXHEALTH
CAP Business Center, Rue d'Abhooz 31
Herstal LIEGE BE
Employees: 312
Phone: 3243642070
MDXHEALTH / MDXH FAQ
Can you describe the business of MDXHEALTH?
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege and currently employs 312 full-time employees. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
What is the current price of MDXH stock?
The current stock price of MDXH is 3.47 USD. The price decreased by -2.53% in the last trading session.
What is the dividend status of MDXHEALTH?
MDXH does not pay a dividend.
How is the ChartMill rating for MDXHEALTH?
MDXH has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is MDXH stock listed?
MDXH stock is listed on the Nasdaq exchange.
What sector and industry does MDXHEALTH belong to?
MDXHEALTH (MDXH) operates in the Health Care sector and the Biotechnology industry.
MDXH Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MDXH. When comparing the yearly performance of all stocks, MDXH is one of the better performing stocks in the market, outperforming 91.33% of all stocks.
MDXH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDXH. MDXH may be in some trouble as it scores bad on both profitability and health.
MDXH Financial Highlights
Over the last trailing twelve months MDXH reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 57.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.12% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MDXH Forecast & Estimates
12 analysts have analysed MDXH and the average price target is 7.18 USD. This implies a price increase of 106.94% is expected in the next year compared to the current price of 3.47.
For the next year, analysts expect an EPS growth of 59.84% and a revenue growth 24.31% for MDXH